Pharma M&A

Klaus Ort

Chapter 120 in Elgar Encyclopedia of Mergers and Acquisitions, 2026, pp 323-325 from Edward Elgar Publishing

Abstract: This chapter examines M&A in the pharmaceutical and biotech sectors. Key drivers include acquiring R&D capabilities, addressing patent expiry (patent cliffs), and adopting personalized medicine. The chapter also highlights valuation methods and the increasing use of specialized licensing deals.

Keywords: Drug Development; Drug Manufacturing; Merger; Acquisitions; Pharma Industry; Biotech; Patent Cliff; License Agreements (search for similar items in EconPapers)
Date: 2026
ISBN: 9781800880856
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.elgaronline.com/doi/10.4337/9781800880863.00126 (application/pdf)
Our link check indicates that this URL is bad, the error code is: 403 Forbidden

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:elg:eechap:20450_120

Ordering information: This item can be ordered from
http://www.e-elgar.com

Access Statistics for this chapter

More chapters in Chapters from Edward Elgar Publishing
Bibliographic data for series maintained by Jack Sweeney ().